Bhabesh Panigrahi, M.S.,MBA’s Post

Yesterday, March 4th, is World Obesity Day. According to data from the #WorldObesityDay official website, by 2035, it is projected that there will be 1.9 billion obese individuals worldwide, with a quarter of the population suffering from obesity. Between 2020 and 2035, childhood obesity is expected to increase by 100%. Being overweight or obese can significantly increase the risk of developing various chronic diseases such as hypertension, type 2 diabetes, and cardiovascular diseases, making it a serious public health concern affecting people's well-being. Obesity medications have now become an important focus in new drug development. Among them, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a key area of interest in the field of obesity drug development due to their excellent clinical data and efficacy. In January of this year, the GLP-1 receptor agonist weight-loss therapy was listed in the "Top 10 Breakthrough Technologies of 2024" by the globally renowned technology publication #MIT Technology Review. #Obesity #Drugdevelopment #WorldObesityDay #GLP-1

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m−2) there were lower rates (events per 100 years of observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placebo). Semaglutide was associated with increased rates of trial product discontinuation. Discontinuations increased as BMI class decreased. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. ** Weight loss was sustained over 4 years ** ClinicalTrials.gov identifier: NCT03574597. In the semaglutide group, 12.0% of patients achieved normal weight status at week 104 (from 0% at baseline), compared with 1.2% (from 0% at baseline) for placebo. BMI classes: healthy (BMI <25 kg m−2), overweight (25 to <30 kg m−2), class I obesity (30 to <35 kg m−2), class II obesity (35 to <40 kg m−2) and class III obesity (BMI ≥40 kg m−2). #longtermweightloss #semaglutide #evidencebased #research #SELECTTrial #weightmanagement #obesitymedicine #advocacy #metabolicdisease https://lnkd.in/gM9Sh_bD

📉 New research shows semaglutide (Wegovy, Ozempic) offers more than double the weight loss of liraglutide (Saxenda, Victoza) for obesity. Semaglutide achieved an average 5.1% weight reduction compared to 2.2% with liraglutide. Higher doses and consistent use are key. #WeightLoss #DiabetesManagement #NovoNordisk #GLP-1

Revolution in Obesity Treatment on the Horizon? 🚀 Exciting developments in healthcare as Roche's strategic acquisition of Carmot Therapeutics starts to bear fruit! Their hopeful contender in the obesity market, CT-388, is showing promising results. Breaking down the first clinical data since the $2.7 billion investment, CT-388 has demonstrated an impressive 18.8% average weight loss, surpassing current market front-runners. It's not just about shedding pounds; all participants experienced over 5% weight loss, with almost half surpassing the 20% milestone. 💉📉 What does this mean for the industry? We're looking at a potential game-changer in both obesity and diabetes care. With weight loss and blood sugar level improvements notable in the study, CT-388's dual-action therapy steps up as a serious contender for best-in-class treatment. This innovation doesn't just signify a win for Roche but also for patients seeking more effective treatments in the battle against obesity and its associated risks. Keep an eye on CT-388 as it progresses, poised to transform lives and the market landscape. 💊🔬 #HealthcareInnovation #ObesityTreatment #DiabetesCare #ClinicalData

A breakthrough weight-loss pill is emerging as potentially more effective than Ozempic, marking a significant advancement in obesity treatment. This innovation offers hope for more effective weight management solutions. #WeightLossInnovation #HealthTech https://lnkd.in/d9jPa66H

TIRZEPATIDE FOR OBESITY TREATMENT AND DIABETES PREVENTION Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The drug leads to significantly improved glycemic control and weight reduction in patients with T2DM, maximizing benefits similar to GLP-1 medications such as semaglutide. Tirzepatide is sold under the brand names Mounjaro for diabetes treatment, and Zepbound for weight loss. Obesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. SURMOUNT-1 was an international, phase 3, double-blind, randomized, placebo-controlled trial of tirzepatide in persons with obesity. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. In this orignal article in The New England Journal of Medicine, Ania M. Jastreboff et al, report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. #tirzepatide #Mounjaro #Zepbound #T2DM #obesity N Engl J Med. 2024 Nov 13. https://lnkd.in/du92YrJq

This is a nice rodent study but a tricky one to translate to humans with diabetes and obesity. Inhaled insulin (exubera) is a recent example on purported acceptability and compliance to treatment that sadly failed to deliver just over 10 years ago (other reasons notwithstanding). I don’t know that once a month regimen necessarily improves compliance over daily or weekly. The discussion has to be around the “forgiveness” of any dosing schedule, with modelling that incorporates real life patient attitudes and behaviours. But any innovation that shows differentiated value is welcome in this space. #diabetes #obesity #drugdevelopment #differentiatedvalueproposition #treatmentcompliance #treatmentadherence

“Beyond blame: Treating obesity as a complex chronic condition Recent discussions surrounding the treatment of obesity have been gaining more traction than usual, particularly in light of groundbreaking medical advancements such as Ozempic/GLP-1 drugs. While traditional perceptions often stigmatize obesity, our understanding of obesity is changing, and how we treat obesity should reflect this new understanding.” Obesity may come from underlying conditions such as thyroid disorders, metabolic syndromes, and even different medications. These conditions along with weight maintenance are important issues in maintaining and improving health with chronic conditions. From scales to blood pressure cuffs, our readings can go seamlessly from patient to the medical team. Look into all we can offer today! https://www.hcunity.com #rpm #ccm #obesity #caremanagement #medicaladvancement #remotepatientmonitoring #metabolic #metabolicdisorders #hypothyroidism

Are you attending the American Diabetes Association’s 84th Scientific Sessions? Don’t miss our interactive symposium, "Striking a Balance: The Role of Glucagon Agonism to Improve Obesity and Metabolic Care." 📅 Date: Sunday, June 23, 2024 ⏰ Time: 7:00 PM - 8:30 PM ET Learn from two renowned obesity experts as they share cutting-edge insights and practice-changing data on novel therapeutic targets like glucagon agonism. This is a unique opportunity to enhance your clinical practice with the latest advancements in obesity treatment. https://bit.ly/4bq5Ovk

New findings reveal the power of combining GLP-1 with other medications for better weight loss results! 📝 GLP-1 analogue therapy alone leads to significant weight loss, with patients losing an average of 11.42 kg over 12 months. ❗ Adding bupropion/naltrexone to GLP-1 therapy boosts weight loss even further, especially for those who initially didn’t respond well to GLP-1 alone. 💉 The study highlights the importance of personalized treatment plans, showing that different patient responses can guide more effective medication strategies. We also embrace combining treatments like bupropion/naltrexone with GLP-1, recognizing the importance of customized care at Enara Health. However, it’s crucial to consider the risks and costs associated with multi-drug treatments too. We advocate for not relying solely on medications but also for developing sustainable lifestyle habits for long-term health. Maintaining balance is essential to optimize obesity management. Link to the study by James Naude, Ali Zentner, MD, FRCPC: https://lnkd.in/gHTWKAMa #ObesityTreatment #HealthInnovation #WeightLoss #GLP1 #Semaglutide #Tirzepatide #Ozempic #Zepbound #Mounjaro #Wegovy #Liraglutide #Obesity #Weight #Health #Healthcare #Lifestyle #Therapy #Drug #HealthyHabits #Naltrexone #Bupropion #InternationalJournalofObesity #Habits #Bariatric Novo Nordisk